| 摘要 |
Therapeutically active compounds of formula (I) or (II) wherein X is -O-, -CH-or -C(O)-; Z is -CHR- or a valence bond; У is -CH-, -C(O)-, CH(OR)-, -O-, -S-; provided that in case Z is a valence bond, Y is not C(O); the dashed line representing an optional double bond in which case Z is -CR12- and Y is -CH-, -C(O)- or -CH(OR)- (in formula II) or -CH- (in formula I); Rand Rare independently H, lower alkyl, lower alkoxy, -NO, halogen, -CF, -OH, benzyloxy or a group of formula (IIIа). Ris H, CN, halogen, -CONH, -COORi, CHNRR, NHC(O)R, NHCHR. NHR, NR21R22. NHC(NH)NHCHor, in case the compound is of formula (II) wherein the optional double bond exists or in case Ror Ris benzyloxy or a group of formula (IIIа) or in case the pyridine ring of formula (I) or (II) is attached to the oxygen atom in 3-, 4- or 5-position, R, can also be -NOor NR,R; Ris H, -NO, CN, halogen, -CONH, -COOR, -CHNRR, -NRR, NHC(O)Ror -NHC(NH)NHCH; Ris alkyl substituted with 1-3 substituents selected from the group consisting of halogen, amino and hydroxy, or carboxy alkyl, in which the alkyl portion is optionally substituted with 1-3 substituents selected from the group consisting of halogen, amino and hydroxyl, -CHRNR,Ror one of the following groups: formula (IVa), (IVb), (IVc), (IVd), (IVe), and pharmaceutically acceptable salts and esters thereof. The compounds are potent inhibitors of Na/Caexchange mechanism. |
